Isoprostane and isofuran lipid mediators accumulate in stored red blood cells and influence platelet function in vitro

Transfusion

Volumn 54, Issue 6, 2014, Pages 1569-1579

  Spinelli, Sherry L ^a   Lannan, Katie L ^a   Casey, Ann E ^a   Croasdell, Amanda ^a   Curran, Timothy M ^a   Henrichs, Kelly F ^a   Pollock, Stephen J ^a   Milne, Ginger A ^b   Refaai, Majed A ^a   Francis, Charles W ^a   Phipps, Richard P ^a   Blumberg, Neil ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; FURAN DERIVATIVE; HEMOGLOBIN; ISOFURAN; ISOPROSTANE DERIVATIVE; PADGEM PROTEIN; PROSTAGLANDIN DERIVATIVE; THROMBOXANE A2; UNCLASSIFIED DRUG;

ARTICLE; CELL FREE SYSTEM; CONTROLLED STUDY; ERYTHROCYTE PRESERVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKAPHERESIS; MASS SPECTROMETRY; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; SUPERNATANT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

BLOOD PLATELETS; DINOPROST; ERYTHROCYTES; F2-ISOPROSTANES; FURANS; HUMANS; IMMUNOASSAY; ISOPROSTANES; REACTIVE OXYGEN SPECIES;

EID: 84902281225     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12485     Document Type: Article

References (43)

1. Carson JL, Duff A, Berlin JA, etal. Perioperative blood transfusion and postoperative mortality. JAMA 1998; 279: 199-205.
2. Schrier SL, Sohmer PR, Moore GL, etal. Red blood cell membrane abnormalities during storage: correlation with in vivo survival. Transfusion 1982; 22: 261-265.
3. Khorana AA, Francis CW, Blumberg N, etal. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008; 168: 2377-2381.
4. Nilsson KR, Berenholtz SM, Garrett-Mayer E, etal. Association between venous thromboembolism and perioperative allogeneic transfusion. Arch Surg 2007; 142: 126-132; discussion 133.
5. Popovsky MA, Moore SB,. Mechanism of transfusion-related acute lung injury. Blood 1991; 77: 2299.
6. Rao SV, Jollis JG, Harrington RA, etal. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555-1562.
7. van Hilten JA, van de Watering LM, van Bockel JH, etal. Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery. BMJ 2004; 328: 1281-1284.
8. Bonaventura J,. Clinical implications of the loss of vasoactive nitric oxide during red blood cell storage. Proc Natl Acad Sci U S A 2007; 104: 19165-19166.
9. Moroff G, Holme S, Keegan T, etal. Storage of ADSOL-preserved red cells at 2.5 and 5.5 degrees C: comparable retention of in vitro properties. Vox Sang 1990; 59: 136-139.
10. Cholette JM, Henrichs KF, Alfieris GM, etal. Washing red blood cells and platelets transfused in cardiac surgery reduces postoperative inflammation and number of transfusions: results of a prospective, randomized, controlled clinical trial. Pediatr Crit Care Med 2012; 13: 290-299.
11. Weinberg JA, McGwin G Jr, Griffin RL, etal. Age of transfused blood: an independent predictor of mortality despite universal leukoreduction. J Trauma 2008; 65: 279-282; discussion 282-4.
12. Blumberg N, Heal JM, Liesveld JL, etal. Platelet transfusion and survival in adults with acute leukemia. Leukemia 2008; 22: 631-635.
13. Grimshaw K, Sahler J, Spinelli SL, etal. New frontiers in transfusion biology: identification and significance of mediators of morbidity and mortality in stored red blood cells. Transfusion 2011; 51: 874-880.
14. Morrow JD, Hill KE, Burk RF, etal. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A 1990; 87: 9383-9387.
15. Morrow JD, Minton TA, Roberts LJ 2nd,. The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins 1992; 44: 155-163.
16. Roberts LJ 2nd, Fessel JP,. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Chem Phys Lipids 2004; 128: 173-186.
17. Roberts LJ, Morrow JD,. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000; 28: 505-513.
18. Pratico D,. F(2)-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 1999; 147: 1-10.
19. Fessel JP, Porter NA, Moore KP, etal. Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension. Proc Natl Acad Sci U S A 2002; 99: 16713-16718.
20. Fukunaga M, Yura T, Badr KF,. Stimulatory effect of 8-Epi-PGF2 alpha, an F2-isoprostane, on endothelin-1 release. J Cardiovasc Pharmacol 1995; 26 Suppl 3: S51-52.
21. Lahaie I, Hardy P, Hou X, etal. A novel mechanism for vasoconstrictor action of 8-isoprostaglandin F2 alpha on retinal vessels. Am J Physiol 1998; 274: R1406-1416.
22. Pratico D, Iuliano L, Mauriello A, etal. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997; 100: 2028-2034.
23. Yura T, Fukunaga M, Khan R, etal. Free-radical-generated F2-isoprostane stimulates cell proliferation and endothelin-1 expression on endothelial cells. Kidney Int 1999; 56: 471-478.
24. Pratico D, Clark CM, Lee VM, etal. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000; 48: 809-812.
25. Davi G, Ciabattoni G, Consoli A, etal. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99: 224-229.
26. Morrow JD, Frei B, Longmire AW, etal. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995; 332: 1198-1203.
27. Schwedhelm E, Bierend A, Maas R, etal. Redox-generated isoprostanes are associated with residual platelet activity in aspirin-treated patients with stable coronary heart disease. J Thromb Haemost 2010; 8: 2662-2670.
28. Milne GL, Gao B, Terry ES, etal. Measurement of F(2-) isoprostanes and isofurans using gas chromatography-mass spectrometry. Free Radic Biol Med 2013; 59: 36-44.
29. Kaufman J, Spinelli SL, Schultz E, etal. Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion. J Thromb Haemost 2007; 5: 788-796.
30. Milne GL, Sanchez SC, Musiek ES, etal. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc 2007; 2: 221-226.
31. Khasawneh FT, Huang JS, Mir F, etal. Characterization of isoprostane signaling: evidence for a unique coordination profile of 8-iso-PGF(2alpha) with the thromboxane A(2) receptor, and activation of a separate cAMP-dependent inhibitory pathway in human platelets. Biochem Pharmacol 2008; 75: 2301-2315.
32. Audoly LP, Rocca B, Fabre JE, etal. Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 2000; 101: 2833-2840.
33. Ting HJ, Khasawneh FT,. Platelet function and Isoprostane biology. Should isoprostanes be the newest member of the orphan-ligand family? J Biomed Sci 2010; 17: 1-13.
34. Yin K, Halushka PV, Yan YT, etal. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets. J Pharmacol Exp Ther 1994; 270: 1192-1196.
35. Benndorf RA, Schwedhelm E, Gnann A, etal. Isoprostanes inhibit vascular endothelial growth factor-induced endothelial cell migration, tube formation, and cardiac vessel sprouting in vitro, as well as angiogenesis in vivo via activation of the thromboxane A(2) receptor: a potential link between oxidative stress and impaired angiogenesis. Circ Res 2008; 103: 1037-1046.
36. Donadee C, Raat NJ, Kanias T, etal. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation 2011; 124: 465-476.
37. Roback JD, Neuman RB, Quyyumi A, etal. Insufficient nitric oxide bioavailability: a hypothesis to explain adverse effects of red blood cell transfusion. Transfusion 2011; 51: 859-866.
38. Cracowski JL,. Isoprostanes: an emerging role in vascular physiology and disease? Chem Phys Lipids 2004; 128: 75-83.
39. Silliman CC, Moore EE, Kelher MR, etal. Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury. Transfusion 2011; 51: 2549-2554.
40. Dumaswala UJ, Zhuo L, Jacobsen DW, etal. Protein and lipid oxidation of banked human erythrocytes: role of glutathione. Free Radic Biol Med 1999; 27: 1041-1049.
41. Yoshida T, AuBuchon JP, Tryzelaar L, etal. Extended storage of red blood cells under anaerobic conditions. Vox Sang 2007; 92: 22-31.
42. Dietrich M, Block G, Hudes M, etal. Antioxidant supplementation decreases lipid peroxidation biomarker F(2)-isoprostanes in plasma of smokers. Cancer Epidemiol Biomarkers Prev 2002; 11: 7-13.
43. Cangemi R, Pignatelli P, Carnevale R, etal. Platelet isoprostane overproduction in diabetic patients treated with aspirin. Diabetes 2012; 61: 1626-1632.